Jim Cramer says investors should consider 3 things before buying a stock

Jim Cramer says investors should consider 3 things before buying a stock


CNBC’s Jim Cramer on Wednesday told investors they should buy stocks based on the company’s financial performance, rather than on whether they like its products.

Better yet, investors should also make sure the stocks they purchase can withstand the currently turbulent economy, he said.

“Doing the homework about the underlying company and knowing how the economy might impact it — that’s often more important than whether you like the product,” the “Mad Money” host said.

“If you don’t know how the companies you own shares in will survive an economic hurricane, or even a [Federal Reserve] tightening or two, then just use the product but don’t own [the company],” he added.

Cramer outlined these three main points to consider when determining whether a company is investable:

  1. Check the company’s financial performance. “How the company’s doing: Is it losing gobs of money, does it have enough capital to last, does it have a path to profitability? If you don’t ask these questions, you’re asking for trouble,” he said.
  2. How crowded is the industry landscape? Cramer noted that if a company operates in an industry that includes a plethora of competitors, it makes it hard to stand out and the stock may not be a great addition to a portfolio.
  3. Can the company withstand a “hurricane” inflation fix from the Fed? “I want you to imagine a hurricane hitting a coastal area. What house do you want to be in? One that’s shielded by a big profit stream with a fortress balance sheet, not to mention a dividend or a buyback? Or one that’s just an idea, or an unprofitable product that happens to have a stock connected to it?” he said.



Source

Real estate could be the big winner in the private credit exodus
Business

Real estate could be the big winner in the private credit exodus

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox. Barely […]

Read More
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Business

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight.  The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]

Read More
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More